Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Br J Haematol ; 188(3): 413-423, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-31468517

RESUMO

The prognostic value of cell of origin (COO) classification and BCL2 expression is not well established in diffuse large B-cell lymphoma (DLBCL) patients with human immunodeficiency virus (HIV) infection in the recent era. Phenotypic patterns were determined by immunohistochemistry (IHC) of pathological samples from patients with HIV-associated DLBCL prospectively enrolled in the French AIDS and Viral Hepatitis CO16 Lymphovir cohort between 2008 and 2015. Molecular subgroup classification into germinal centre B-cell (GCB) and non-GCB subtypes was determined using the Hans algorithm. Among 52 samples of systemic DLBCL subjected to centralized pathological analysis, 25 of the 42 tested for BCL2 expression were positive. Samples were further classified into GCB (n = 19) and non-GCB (n = 16) subtypes and 17 remained unclassified. In multivariable analysis, BCL2 expression was an independent pejorative prognostic biomarker [4-year progression-free survival (PFS): 52% for BCL2+ vs. 88% for BCL2- , P = 0·02] and tended to reduce 4-year overall survival (OS) (63% for BCL2+ vs. 88% for BCL2- , P = 0·06). The difference between CGB and non-GCB subtypes on PFS and OS did not reach significance (4-year PFS: 79% for GCB vs. 53% for non-GCB, P = 0·24 and 4-year OS: 78% for GCB vs. 69% for non-GCB, P = 0·34). BCL2 expression determined by IHC is an independent pejorative prognostic biomarker in HIV-associated DLBCL in the recent era. This supports the investigation of new therapeutic strategies in patients with BCL2 expression.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Regulação Neoplásica da Expressão Gênica , Infecções por HIV , HIV-1/metabolismo , Linfoma Difuso de Grandes Células B , Proteínas Proto-Oncogênicas c-bcl-2/biossíntese , Adulto , Ciclofosfamida/administração & dosagem , Intervalo Livre de Doença , Doxorrubicina/administração & dosagem , Feminino , Infecções por HIV/tratamento farmacológico , Infecções por HIV/metabolismo , Infecções por HIV/mortalidade , Humanos , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Linfoma Difuso de Grandes Células B/metabolismo , Linfoma Difuso de Grandes Células B/mortalidade , Masculino , Pessoa de Meia-Idade , Prednisona/administração & dosagem , Rituximab/administração & dosagem , Taxa de Sobrevida , Vincristina/administração & dosagem
2.
Ann Pathol ; 35(4): 294-305, 2015 Aug.
Artigo em Francês | MEDLINE | ID: mdl-26188673

RESUMO

May-Grünwald-Giemsa (MGG) stain is a Romanowsky-type, polychromatic stain as those of Giemsa, Leishman and Wright. Apart being the reference method of haematology, it has become a routine stain of diagnostic cytopathology for the study of air-dried preparations (lymph node imprints, centrifuged body fluids and fine needle aspirations). In the context of their actions of promoting the principles of quality assurance in cytopathology, the French Association for Quality Assurance in Anatomic and Cytologic Pathology (AFAQAP) and the French Society of Clinical Cytology (SFCC) conducted a proficiency test on MGG stain in 2013. Results from the test, together with the review of literature data allow pre-analytical and analytical steps of MGG stain to be updated. Recommendations include rapid air-drying of cell preparations/imprints, fixation using either methanol or May-Grünwald alone for 3-10minutes, two-step staining: 50% May-Grünwald in buffer pH 6.8 v/v for 3-5minutes, followed by 10% buffered Giemsa solution for 10-30minutes, and running water for 1-3minutes. Quality evaluation must be performed on red blood cells (RBCs) and leukocytes, not on tumour cells. Under correct pH conditions, RBCs must appear pink-orange (acidophilic) or buff-coloured, neither green nor blue. Leukocyte cytoplasm must be almost transparent, with clearly delineated granules. However, staining may vary somewhat and testing is recommended for automated methods (slide stainers) which remain the standard for reproducibility. Though MGG stain remains the reference stain, Diff-Quik(®) stain can be used for the rapid evaluation of cell samples.


Assuntos
Corantes , Citodiagnóstico/normas , Amarelo de Eosina-(YS) , Azul de Metileno , Guias de Prática Clínica como Assunto , Coloração e Rotulagem/métodos , Automação , Corantes Azur , Biologia Celular/organização & administração , Corantes/química , Citodiagnóstico/métodos , Amarelo de Eosina-(YS)/química , Eritrócitos/ultraestrutura , França , Humanos , Concentração de Íons de Hidrogênio , Leucócitos/ultraestrutura , Azul de Metileno/química , Organelas/ultraestrutura , Garantia da Qualidade dos Cuidados de Saúde , Reprodutibilidade dos Testes , Sociedades Científicas , Coloração e Rotulagem/instrumentação , Coloração e Rotulagem/normas , Fixação de Tecidos/métodos , Xantenos
3.
Ann Pathol ; 32(3): 177-83, 2012 Jun.
Artigo em Francês | MEDLINE | ID: mdl-22748331

RESUMO

When considering the number of thyroid fine-needle aspirations performed not only in France but also in the world, then thyroid pathology, as well as Pap smears, represents the main pathology based on cytological diagnoses. Decisions of clinical follow-up or of surgical treatments will be done based on the cytological results. Until recently, neither official nor consensual terminology has been adopted despite classifications by experts having been proposed. The Bethesda terminology, published in 2010, in English, is linked with a percentage of risk cancer for each of its diagnostic category and with a suitable treatment. Furthermore, this terminology allows the possibility of standardized management for the patients and the opportunity of further assessment of the cytological diagnoses. Therefore, the French Society of Clinical Cytology has decided to publish this official French version of the Bethesda terminology. Its use is highly recommended.


Assuntos
Neoplasias da Glândula Tireoide/classificação , Neoplasias da Glândula Tireoide/patologia , Biópsia por Agulha Fina , Humanos
4.
Ther Adv Med Oncol ; 12: 1758835920937972, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32684990

RESUMO

BACKGROUND: Few data are available on programmed cell-death-protein-1-ligand-1 (PD-L1) expression on large-cell neuroendocrine carcinomas of the lung (LCNECs). We analyzed PD-L1 expression on tumor (TCs) and inflammatory cells (ICs) from LCNEC patients to assess relationships between this expression, clinical characteristics, and disease outcomes. METHODS: PD-L1 expression was determined by immunohistochemistry with monoclonal antibody 22C3 in consecutive LCNEC patients managed in 17 French centers between January 2014 and December 2016. RESULTS: After centralized review, only 68 out of 105 (64%) patients had confirmed LCNEC diagnoses. Median overall survival (OS) (95% CI) was 11 (7-16) months for all patients, 7 (5-10), 21 (10-not reached) and not reached months for metastatic, stage III and localized forms (p = 0.0001). Respectively, 11% and 75% of the tumor samples were TC+ and IC+, and 66% had a TC-/IC+ profile. Comparing IC+ versus IC- metastatic LCNEC, the former had significantly longer progression-free survival [9 (4-13) versus 4 (1-8) months; p = 0.03], with a trend towards better median OS [12 (7-18) versus 9.5 (4-14) months; p = 0.21]. Compared to patients with TC- tumors, those with TC+ LCNECs tended to have non-significantly shorter median OS [4 (1-6.2) versus 11 (8-18) months, respectively]. Median OS was significantly shorter for patients with TC+/IC- metastatic LCNECs than those with TC-IC+ lesions (2 versus 8 months, respectively; p = 0.04). CONCLUSION: TC-/IC+ was the most frequent PD-L1-expression profile for LCNECs, a pattern quite specific compared with non-small-cell lung cancer and small-cell lung cancer. IC PD-L1 expression seems to have a prognostic role.

5.
Sex Dev ; 13(5-6): 271-277, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-32961533

RESUMO

Tetragametic chimeras are due to the fusion of 2 different zygotes after fertilization. When occurring between embryos of different chromosomal sex, the phenotype ranges from fertile individuals to infertile patients and even to patients with variations in sex development. Here, we report 3 new cases of XX/XY chimeras, one in a young boy carrying an abnormal gonad which turned out to be an ovary and 2 in phenotypically normal infertile men, one of whom had been diagnosed previously as a XX-SRY negative male. These cases highlight the importance of combining several cytogenetic and molecular techniques on different tissues for a proper diagnosis and an appropriate prognosis.

6.
Eur J Obstet Gynecol Reprod Biol ; 197: 54-8, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26717495

RESUMO

OBJECTIVE: The primary aim of our study was to determine the prevalence of macroscopic deciduosis Found randomly in Cesarean sections and the secondary objective to determine the association with any obstetrical complications or adverse effects. METHODS: This is a unicenter prospective study from 01/08/2011 to 01/02/2014. During the study period 307 consecutive Cesarean sections were performed with 31 biopsy proven cases of macroscopic deciduosis in the ovary, uterine and fallopian tube serosa. RESULTS: The mean age of the patients was 31.2 ± 5.4 years (range 13-43), the mean Body Mass Index was 26.3 ± 5.8 (range 15-48)kg/m(2), the mean term of Cesarean was 270 ± 25 days, and the mean fetal weight was 3094 ± 809 g. The majority of patients were Caucasian (n=175, 57.0%). Patients with deciduosis had a greater BMI (28.4 ± 5.3 kg/m(2) vs 25.7 ± 5.8 kg/m(2), p<0.05). The presence of pain was more frequent in the deciduosis group (10.1%, OR 5.78, 95%, CI [2.41-13.87], p<0.001). CONCLUSION: Deciduosis is a benign lesion during pregnancy that is not correlated with obstetrical complications. Our study has shown that this physiological phenomenon is more frequent that originally thought, being present in 10% of the Cesarean sections, and is associated with abdominal pain during pregnancy.


Assuntos
Cesárea , Coristoma/epidemiologia , Decídua , Doenças das Tubas Uterinas/epidemiologia , Doenças Ovarianas/epidemiologia , Complicações na Gravidez/epidemiologia , Doenças Uterinas/epidemiologia , Dor Abdominal/etiologia , Adulto , Biópsia , Índice de Massa Corporal , Coristoma/complicações , Coristoma/patologia , Estudos de Coortes , Doenças das Tubas Uterinas/complicações , Doenças das Tubas Uterinas/patologia , Feminino , Humanos , Imuno-Histoquímica , Doenças Ovarianas/complicações , Doenças Ovarianas/patologia , Sobrepeso/epidemiologia , Gravidez , Complicações na Gravidez/patologia , Estudos Prospectivos , Membrana Serosa/patologia , Doenças Uterinas/complicações , Doenças Uterinas/patologia
7.
Arch Pathol Lab Med ; 129(3): 403-6, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15737040

RESUMO

Malignant deciduoid mesothelioma, a rare phenotype of epithelioid mesothelioma, arises more commonly from the peritoneum of young women, but it is also reported in the pleura of elderly people. We report a case of malignant deciduoid mesothelioma that occurred in a 41-year-old woman after cesarean section and was initially misdiagnosed as pseudotumoral deciduosis. Microscopically, the tumor was entirely composed of deciduoid areas, and only scattered tumor cells were positive for calretinin and keratin 5/6. The patient died 14 months after the first operation. This observation confirms the poor prognosis of this entity and the importance of the differential diagnosis of pseudotumoral deciduosis.


Assuntos
Coristoma/diagnóstico , Endométrio/patologia , Mesotelioma/diagnóstico , Omento/patologia , Doenças Ovarianas/diagnóstico , Neoplasias Ovarianas/diagnóstico , Neoplasias Peritoneais/diagnóstico , Doenças Uterinas/diagnóstico , Neoplasias Uterinas/diagnóstico , Adulto , Diagnóstico Diferencial , Feminino , Humanos , Doenças Peritoneais/diagnóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA